Dr. Ai on the FDA Approval of Mogamulizumab in CTCL
5 意见
administrator
08/09/23
Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.
显示更多
脸书评论
没有找到评论